[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Hemogenyx Pharmaceuticals Plc (HEMO.LN)

Hemogenyx Pharmaceuticals Plc (HEMO.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Hemogenyx Pharmaceuticals Plc 6 Heddon Street London W1B 4BT GBR

https://www.hemogenyx.com

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Hemogenyx Pharmaceuticals PLC is clinical-stage biotechnology focused on the discovery, development and commercialisation of treatments relating to the treatment of blood cancers, certain solid cancers, autoimmune diseases, and viral infections. The products under development are designed to address a range of problems that occur with current standard of care treatments. The Group has one reportable segment, the discovery, development, and commercialisation of treatments relating to blood and immune system disorders and viral infections, and administrative functions in the United Kingdom. It has its presence in United Kingdom; and United States.

Key Statistics

Overview:

Market Capitalization, $K 56,134
Shares Outstanding, K 6,800
% of Insider Shareholders 9.95%
% of Institutional Shareholders 0.18%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -9,760 K

Growth:

1-Year Return 365.19%
3-Year Return 61.68%
5-Year Return -14.29%
5-Year Revenue Growth 0.00%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm -1.71
Dividend Payout Ratio 0.00%
Most Recent Split 1-400 on 12/13/24

HEMO.LN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Return-on-Equity % -932.71%
Return-on-Assets % -232.74%
Profit Margin % 0.00%
Debt/Equity 1.31
Price/Sales N/A
Price/Book 46.96
Book Value/Share 0.18
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.